Welcome to our dedicated page for Bausch Health Companies news (Ticker: BHC), a resource for investors and traders seeking the latest updates and insights on Bausch Health Companies stock.
Bausch Health Companies Inc. reports news on its global diversified pharmaceutical business, including financial results, guidance, debt refinancing activity and updates from its operating businesses. The company develops, manufactures and markets products in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health through its controlling interest in Bausch + Lomb.
Recurring company updates include Salix gastroenterology programs, Ortho Dermatologics skincare and patient-support initiatives, Solta Medical aesthetic device launches, and quarterly performance for Bausch Health excluding Bausch + Lomb. News also covers product availability, regulatory clearances for medical aesthetic devices, clinical-program disclosures and capital-structure actions.
Bausch Health (NYSE:BHC) announced that its aesthetic business, Solta Medical, completed the acquisition of Wuhan Shibo Zhenmei Technology Co., Ltd., the Shibo group's aesthetics distribution business, effective December 1, 2025. The Shibo group, a distribution partner for more than a decade, becomes a wholly owned Solta Medical subsidiary in China and assumes full responsibility for distributing Solta Medical products, including Thermage FLX.
The transaction is intended to deepen local presence, provide direct customer insight, speed market execution, and support growing demand for aesthetic treatments in China.
Bausch Health (NYSE:BHC) commenced offers on November 24, 2025 to exchange up to $1.6 billion aggregate principal of its outstanding 4.875% and 11.00% Senior Secured Notes due 2028 for new 10.00% Senior Secured Notes due 2032 issued by a wholly owned subsidiary.
Key terms: Exchange Consideration per $1,000 is $787.50 (4.875% notes) and $920.00 (11.00% notes); an Early Exchange Premium $100 per $1,000 applies for tenders by Dec 8, 2025; offers expire Dec 23, 2025. New Notes will be fungible with the issuer's existing 10.00% notes due 2032 and are subject to eligibility, customary conditions and a transaction support agreement covering ~$1,545 million of existing notes.
Bausch Health (NYSE:BHC) said Jean-Jacques Charhon, executive vice president and chief financial officer, will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference in Coral Gables, Florida on December 2, 2025.
The session is scheduled for 10:50 a.m. – 11:10 a.m. ET and a live audio webcast will be available via the company’s Investor Relations website at http://ir.bauschhealth.com/events-and-presentations. A replay will be posted on the investor site after the event.
Bausch Health (NYSE:BHC) and its dental business OraPharma announced commercial expansion of Arestin into Canada and Puerto Rico on November 5, 2025, aiming to improve access to periodontal disease treatments and strengthen distributor and dental professional partnerships.
Arestin is described as the only FDA‑approved locally applied antibiotic for use with scaling and root planing and is supported by over 20 years of clinical experience. The release highlights high regional disease prevalence and includes safety and prescribing information for Arestin.
Bausch Health (NYSE:BHC) reported third quarter 2025 consolidated revenue of $2.68 billion, up 7% year-over-year (5% organic), GAAP net income attributable to Bausch Health of $179 million, and consolidated adjusted EBITDA (non-GAAP) of $986 million (includes an $81 million acquired IPR&D charge).
Key operational highlights: tenth consecutive quarter of year-over-year revenue and adjusted EBITDA growth excluding Bausch + Lomb; completed acquisition of DURECT and added Larsucosterol with FDA Breakthrough Therapy Designation; redeemed ~$601 million of 9.25% notes and repaid a $300 million receivables facility post-quarter. Company raised full-year 2025 revenue and adjusted EBITDA guidance.
Bausch Health (NYSE: BHC) announced that shareholders approved the Amended and Restated Shareholder Rights Plan Agreement at a special meeting held on October 7, 2025. The Rights Plan is dated April 14, 2025 and was amended and restated on August 25, 2025. The company said the final vote tabulation will be filed with the U.S. SEC on a Form 8-K and will be available on SEDAR+ and the company website.
This notice confirms shareholder ratification, and indicates the company will publicly report the detailed vote results via regulatory and company channels.
Bausch Health (NYSE:BHC) announced that its aesthetic business, Solta Medical, will be featured on Lifetime TV's The Balancing Act, showcasing its portfolio of non-invasive skin rejuvenation technologies. The segment will spotlight three key products: Thermage® FLX for skin tightening using radiofrequency technology, Clear + Brilliant® Touch for early aging signs treatment, and Fraxel FTX™ for addressing fine lines and scars.
The program, hosted by Montel Williams and Olga Villaverde, will air on October 2 and October 24, 2025, featuring demonstrations and expert insights from dermatologists. The segment will be available on multiple streaming platforms including Sling TV, Hulu, Live, and Fubu.
Bausch Health (NYSE:BHC) has scheduled its third quarter 2025 financial results announcement for October 29, 2025, after market close. The company will host a conference call and webcast at 5:00 p.m. U.S. EDT to discuss the results and provide a business update.
All presentation materials will be available on the company's Investor Relations website before the call begins. A replay of the conference call will also be accessible through the investor relations website at ir.bauschhealth.com.
Bausch Health (NYSE:BHC) and its dentistry business OraPharma have launched OraTalks, a new podcast series focused on modern dentistry challenges. The inaugural nine-episode season, hosted by industry expert Melissa K. Turner, will explore critical topics including sleep disorders, women's health, and social determinants in oral healthcare.
The podcast aims to address significant oral health challenges, considering that nearly 65 million Americans are affected by gum disease. OraTalks will be available on major platforms like Apple Podcasts and Spotify starting September 29, 2025, with registration available at oratalks.com for exclusive updates.
Bausch Health (NYSE:BHC) has successfully completed its acquisition of DURECT Corporation for $1.75 per share, representing a total upfront cash payment of $63 million. The deal includes potential additional milestone payments of up to $350 million based on net sales achievements.
The acquisition brings DURECT's lead asset larsucosterol, an FDA Breakthrough Therapy-designated epigenetic modulator for alcohol-associated hepatitis (AH), into Bausch Health's hepatology pipeline. A Phase 3 program is being planned to evaluate the treatment's safety and efficacy. Currently, there are no approved therapies for AH, with existing supportive care resulting in approximately 30% mortality within 90 days of hospitalization.
The tender offer secured approximately 19,984,767 shares, representing about 62% of DURECT's outstanding common stock. Following the merger, DURECT has become a wholly owned subsidiary of Bausch Health and will be delisted from Nasdaq.